Clinical Trial Update: A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial results for oral tofacitinib (CP-690,550) as maintenance therapy in ulcerative colitis were completed and results were posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2017-05-18